News
Pharmaceutical Technology on MSN16d
FDA grants accelerated approval to Novartis’ Vanrafia for IgANThe approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.
Investor's Business Daily on MSN15d
Novartis Has A Slight Edge On Travere — Why Analysts Aren't WorriedNovartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...
Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...
Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...
NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of ...
Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por Novartis en 2023 por 3.200 millones de dólares. 'Vanrafia' está indicado ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback